Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKP.L Regulatory News (SKP)

  • There is currently no data for SKP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

24 Sep 2008 15:14

RNS Number : 2159E
Skyepharma PLC
24 September 2008
 



For filings with the FSA include the annex

For filings with issuer exclude the annex 

TR-1: Notifications of Major Interests in Shares

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Skyepharma PLC GB00B3BFNB64

2. Reason for notification (yes/no)

An acquisition or disposal of voting rights

N/A

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached 

N/A

An event changing the breakdown of voting rights

N/A

Other (please specify): The ISIN for Skyepharma Plc ordinary shares has changed from GB0008123571 to GB00B3BFNB64.

Yes

3. Full name of person(s) subject to notification obligation:

UBS INVESTMENT BANK

4. Full name of shareholder(s) (if different from 3):

UBS AG London Branch

5. Date of transaction (and date on which the threshold is crossed or reached if different):

22 September 2008

6. Date on which issuer notified:

24 September 2008

7. Threshold(s) that is/are crossed or reached:

4.43%

8: Notified Details

A: Voting rights attached to shares

Class/type of shares

If possible use ISIN code

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of shares

Number of voting rights

Number of shares

Number of voting rights

Percentage of voting rights

Direct

Indirect

Direct

Indirect

GB00B3BFNB64

-

-

361,155

361,155

-

4.43%

4.43%

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date

Exercise/ conversion period/date 

No. of voting rights that may be acquired (if the instrument exercised/converted)

Percentage of voting rights

-

-

-

-

-

Total (A+B)

Number of voting rights

Percentage of voting rights

361,155

4.43%

9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable:

Proxy Voting:

10. Name of proxy holder:

-

11. Number of voting rights proxy holder will cease to hold:

-

12. Date on which proxy holder will cease to hold voting rights:

-

13. Additional information:

14 Contact name:

Cintia Goertz/Sarah Cottle

15. Contact telephone number:

0207 5684 981

For notes on how to complete form TR-1 please see the FSA website. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLXZLFLVKBEBBX
Date   Source Headline
3rd Apr 201411:51 amRNSDirector/PDMR Shareholding
3rd Apr 201411:50 amRNSDirector/PDMR Shareholding
1st Apr 20144:58 pmRNSAnnual Financial Report
31st Mar 20147:45 amRNSProposed Placing and Open Offer to Raise £112m
31st Mar 20147:00 amRNSFinal Results
26th Mar 20147:00 amRNSNotice of Results
6th Mar 20142:44 pmRNSDirector Declaration
5th Mar 20147:00 amRNSBoard Changes
4th Mar 20149:47 amRNSHolding(s) in Company
3rd Mar 20143:38 pmRNSHolding(s) in Company
28th Feb 20147:02 amRNSBoard Change
21st Feb 20142:53 pmRNSAnoro Receives Positive Opinion from CHMP
10th Feb 20145:59 pmRNSHolding(s) in Company
10th Feb 20147:00 amRNSflutiform launched in France
4th Feb 20143:19 pmRNSHolding(s) in Company
31st Jan 20147:00 amRNSTrading Update
22nd Jan 20142:50 pmRNSPositive step towards flutiform approval in Spain
19th Dec 20137:45 amRNSANORO ELLIPTA RECEIVES REGULATORY APPROVAL IN US
18th Dec 20132:52 pmRNSUpdate on Lyon manufacturing facility
4th Dec 20137:00 amRNSCapital Markets meeting & flutiform sales update
25th Nov 20135:54 pmRNSDirector/PDMR Shareholding
25th Nov 201310:57 amRNSFurther re Directorate Change
19th Nov 20137:00 amRNSPartner Kyorin launches flutiform in Japan
11th Nov 201311:41 amRNSHolding(s) in Company
11th Nov 201310:42 amRNSDirector/PDMR Shareholding
30th Oct 201311:38 amRNSHolding(s) in Company
10th Oct 20137:00 amRNSInterim Management Statement
24th Sep 20133:39 pmRNSHolding(s) in Company
23rd Sep 20134:31 pmRNSHolding(s) in Company
23rd Sep 20139:31 amRNSHolding(s) in Company
20th Sep 20138:39 amRNSCapital Markets Day, Muttenz, Switzerland
20th Sep 20138:20 amRNSRELVAR ELLIPTA Receives Approval in Japan
20th Sep 20137:00 amRNSflutiform approved in Japan
19th Sep 20132:02 pmRNSHolding(s) in Company
19th Sep 20131:54 pmRNSHolding(s) in Company
19th Sep 20137:00 amRNSflutiform trial for COPD initiated in Europe
22nd Aug 201311:11 amRNSAppointment of Andrew Derodra as CFO
19th Aug 20134:02 pmRNSHolding(s) in Company
15th Aug 20135:20 pmRNSDirector/PDMR Shareholding
15th Aug 20137:00 amRNSHalf Yearly Report
14th Aug 20133:38 pmRNSHolding(s) in Company
1st Aug 20134:08 pmRNSHolding(s) in Company
31st Jul 20139:28 amRNSflutiform recommended for approval in Japan
8th Jul 20137:00 amRNSNotice of Results
20th Jun 201311:00 amRNSflutiform launch in Italy
19th Jun 201312:31 pmRNSHolding(s) in Company
10th Jun 201310:35 amRNSHolding(s) in Company
4th Jun 20134:40 pmRNSSecond Price Monitoring Extn
4th Jun 20134:35 pmRNSPrice Monitoring Extension
3rd Jun 20137:00 amRNSPresenting at Jefferies 2013 Healthcare Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.